IRCT20210519051345N4尚未招募未知
In vivo bioequivalence study of Azithromycin 500 mg tablet manufactured by Fatak shimin Co. in comparison to innovator product Zithromax®
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 60 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart and Kidney),
- •Age (20-60)
排除标准
- •history of cardiovascular, liver and kidney disease,
- •alcohol and drug addiction,
- •history of drug allergy
研究者
相似试验
尚未招募
Unknown
In-vivo Bioequivalence Study of Azithromycin 500 mg Capsules of The Test Drug (ZITHROSAD 500 mg Cap., Sajjad Darou, Iran)IRCT20200105046010N107Sajad darou shargh24
尚未招募
不适用
Investigating the in vivo bioequivalence of Azithromycin 250 mg capsuleIRCT20210519051345N13Tabriz University of Medical Sciences24
已完成
不适用
Bioequivalence study of Azithromycin 200 mg/5mL powder for oral suspension in healthy Thai volunteer under fasting conditioTCTR20180109003All Research Co., Ltd.42
招募中
不适用
In-vivo Bioequivalence study of Azithromycin capsules 250 mg with brand drugs (ZITHROMAX® 250 mg Pfizer, Ireland)IRCT20200105046010N37Kharazmi Pharmaceutical Co24
已完成
不适用
Bioequivalence study of Azithromycin 500 mg tabletThis study is performed on healthy volunteers..IRCT20200623047902N13Sanamed pharma company24